-

Dexcom Publishes Annual Sustainability Report

  • Report advances Dexcom’s environmental, social, and governance (ESG) transparency by providing new disclosures, including company’s first greenhouse gas emissions inventory and enhanced human capital reporting

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report, which provides updates on key environmental, social, and governance (ESG) initiatives that are aligned with Dexcom’s core values and business strategy.

“At Dexcom, we recognize and value the significant trust placed in our company not only by our global customer base, but also our employees and their families, our communities and our shareholders,” said Kevin Sayer, chairman, president and CEO of Dexcom. “We believe that by advancing the interests of our key stakeholders, we can both support the success of our business and drive greater health and economic benefits for our users and global health systems.”

Dexcom’s sustainability initiatives are integrated as foundational elements of the company’s core values and business strategy. The annual report is once again framed according to the company’s four core values: Listen, Think Big, Be Dependable, and Serve with Integrity.

Highlights from this year’s report include:

  • Enhanced reporting on environmental initiatives, including the company’s inaugural greenhouse gas emissions disclosure and Task Force on Climate-Related Financial Disclosures (TCFD) Index
  • Significant additions to human capital reporting that demonstrate the company’s ongoing commitment to diversity, equity, and inclusion, including Dexcom’s latest EEO-1 report, and additional disclosure related to the diversity of those serving in senior roles. In addition, the company has committed to work with an external consultant to conduct an adjusted pay gap analysis with respect to gender and ethnicity, with quantitative disclosure to come in the company’s 2024 Sustainability Report.
  • Updates related to the company’s multifaceted access to healthcare strategy, which has resulted in several key expansions of coverage for people with diabetes in the U.S. and international markets.

Dexcom’s annual Sustainability Report can be found on the company’s investor relations site at the following link: Dexcom Sustainability Report. All data in the report reflects fiscal year 2022, unless noted otherwise.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

DexCom, Inc.

NASDAQ:DXCM

Release Versions

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

More News From DexCom, Inc.

Dexcom Reports Second Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Second Quarter 2026 Financial Results...

Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program

SAN DIEGO--(BUSINESS WIRE)--Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. Participation in the TEMPO pilot will allow Dexcom...

Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM whi...
Back to Newsroom